Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Other solid neoplasm 2Head & Neck 2Genitourinary 2Endocrine 2CNS 2Thoracic 1NET 1Lymphoid 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Solid Tumors 1Locally Advanced Solid Tumors 1

Interventions

Nivolumab 3Ipilimumab 3pembrolizumab 2entrectinib 2cobimetinib 2Pemetrexed 2Cisplatin 2tovorafenib 1sotorasib 1relatlimab 1pralsetinib 1larotrectinib 1ipatasertib 1inavolisib 1daratumumab 1atezolizumab 1alectinib 1PM 01183 1Midazolam 1Carboplatin 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × entrectinib × Other solid neoplasm × Clear all
NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Hoffmann-La Roche

Phase 2 Active not recruiting
920 enrolled 1 FDA
Other solid neoplasm

Solid Tumors

NCT02097810 2021-06-09

STARTRK-1

Hoffmann-La Roche

Phase 1 Completed
84 enrolled 1 FDA
Other solid neoplasm

Locally Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡